Grail shares surge on FDA panel approval, but pricing remains key variable
GRAL GRAIL Inc
$140.58 +6.01%
View chart & analysis → - 1The FDA Medical Devices Advisory Committee's Molecular and Clinical Genetic Diagnostics Panel voted in favor of the safety, benefits, and effectiveness of the Galleri test.
- 2Grail shares surged, recording an 80% increase over the past month.
- 3Given Grail's current list price of $949, the price insurers are willing to pay is a key risk factor.
So what's the key point?
An FDA advisory committee gave a positive evaluation of Grail's testing technology. While the stock price rose 80%, the amount insurance companies are willing to pay in the future is important.
Source Nasdaq +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.